

3. BÖLÜM

SIK GÖRÜLEN LENFOİD NEOPLAZİLERE YAKLAŞIMDA MORFOLOJİK VE İMMÜNOHİSTOKİMYASAL ALGORİTMALAR

Çiğdem ÖZDEMİR¹

GİRİŞ

Lenfomalar immün hücrelerin malignitesidir, B hücreleri, T hücreleri ve NK hücrelerinden köken alır. İki ana gruba ayrılır Hodgkin Lenfoma (HL) ve Non- Hodgkin Lenfoma (NHL). HL ise klasik tip ve non klasik tip olarak ayrılır. NHL'lar ise B hücreli, T hücreli ve Natural Killer (NK) hücreli olarak gruplandırılır (1). Aklımıza gelen her organda lenfoma görülebilir bulunun ile birlikte lenfoma lenf nodu kaynaklı ise nodal lenfoma, lenf nodu dışındaki başka bir organ ya da bölgeden kaynaklı ise ektranodal lenfoma diye adlandırılır (2). Nodal lenfomalar ve ektranodal lenfomalar benzer hücrelerden kaynaklanabileceği gibi, bazı organlara spesifik lenfomalar da vardır. Lenfoma sınıflandırılması Dünya Sağlık Örgütü tarafından morfolojik, immünofenotipik, genetik ve klinik bulgulara göre yapılmaktadır (3). Zaman geçtikçe yeni provizyonel antiteler eklenmekte ve sınıflamalar karmaşıklıktıkça lenfomaları anlayabilmemiz tanı koymamız zorlaşmaktadır.

Nodal ve ektranodal lenfomalarda infiltrasyon paternine, hücre morfolojise göre ve immünofenotipik özelliklerine algoritmalar oluşturmak, lenfomaların ayırıcı tanımlarını yapabilmemizde kolaylıklar sağlayacaktır.

NODAL LENFOMALARDA İNİLTRASYON PATERNİ VE HÜCRE MORFOLOJİSİ

Lenf nodundan kaynaklanan lenfomalar genel olarak lenf nodunu diffüz ya da noduler/foliküler paternde etkiler. Lenfomaların çoğunluğu diffüz paternde infiltrasyon yapar (3, 4), daha az miktarı nodüler/foliküler paternde infiltrasyon gösterir (3, 5-7). Diffüz paternde infiltrasyon yapan lenfomalar değişik hücre morfolojileri göstermektedir. Anaplastik morfoloji (3, 7-10), büyük hücre morfolojisi (2, 3, 5, 7, 11-14), küçük-orta büyüklükte hücre morfolojisi (3, 15-18), burkitt benzeri morfoloji (14), Hodgkin/Reed-sternberg hücre morfolojisi (Şekil 1) (10, 19, 20).

Nodüler/foliküler paternde infiltrasyon yapan lenfomalar genellikle küçük- orta büyüklükte hücre morfolojisinde olup (3, 7, 15-18), Hodgkin/Reed-sternberg hücre morfolojisi de gösterebilir (Şekil 2) (19, 20).

EKSTRANODAL LENFOMALARDA İNİLTRASYON PATERNİ VE HÜCRE MORFOLOJİSİ

Deri ektranodal lenfomaların sık görüldüğü organlardandır. Deri lenfomaları genellikle diffüz

¹ Dr. Öğr. Üyesi, Afyonkarahisar Sağlık Bilimleri Üniversitesi Tıp Fakültesi Patoloji AD, drcozdemir75@hotmail.com

KAYNAKLAR

- Mugnaini EN, Ghosh N. Lymphoma. *Prim Care*. 2016;43(4):661-75.
- Jaffe ES. Diagnosis and classification of lymphoma: Impact of technical advances. *Semin Hematol*. 2019;56(1):30-6.
- Swerdlow SH CE, Harris NL, et al. . WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon: International Agency for Research on Cancer 2017.
- Jiang M, Bannani NN, Feldman AL. Lymphoma classification update: B-cell non-Hodgkin lymphomas. *Expert Rev Hematol*. 2017;10(5):405-15.
- Randall C, Fedoriw Y. Pathology and diagnosis of follicular lymphoma and related entities. *Pathology*. 2020;52(1):30-9.
- Van den Brand M, Mathijssen JJ, Garcia-Garcia M, Hebeda KM, Groenen PJ, Falini B, et al. Immunohistochemical differentiation between follicular lymphoma and nodal marginal zone lymphoma--combined performance of multiple markers. *Haematologica*. 2015;100(9):e358-60.
- De Leval L. Approach to nodal-based T-cell lymphomas. *Pathology*. 2020;52(1):78-99.
- Haralambieva E, Pulford KA, Lamant L, Pileri S, Roncador G, Gatter KC, et al. Anaplastic large-cell lymphomas of B-cell phenotype are anaplastic lymphoma kinase (ALK) negative and belong to the spectrum of diffuse large B-cell lymphomas. *Br J Haematol*. 2000;109(3):584-91.
- Pan Z, Hu S, Li M, Zhou Y, Kim YS, Reddy V, et al. ALK-positive Large B-cell Lymphoma: A Clinicopathologic Study of 26 Cases With Review of Additional 108 Cases in the Literature. *Am J Surg Pathol*. 2017;41(1):25-38.
- Tsuyama N, Sakamoto K, Sakata S, Dobashi A, Takeuchi K. Anaplastic large cell lymphoma: pathology, genetics, and clinical aspects. *J Clin Exp Hematop*. 2017;57(3):120-42.
- Gascoyne DM, Banham AH. The significance of FOXP1 in diffuse large B-cell lymphoma. *Leuk Lymphoma*. 2017;58(5):1037-51.
- Sukswai N, Lyapichev K, Khoury JD, Medeiros LJ. Diffuse large B-cell lymphoma variants: an update. *Pathology*. 2020;52(1):53-67.
- Jain P, Wang M. Mantle cell lymphoma: 2019 update on the diagnosis, pathogenesis, prognostication, and management. *Am J Hematol*. 2019;94(6):710-25.
- Grimm KE, O'Malley DP. Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of haematopoietic and lymphoid tissues. *Ann Diagn Pathol*. 2019;38:6-10.
- O'Malley DP, Lee JP, Bellizzi AM. Expression of LEF1 in mantle cell lymphoma. *Ann Diagn Pathol*. 2017;26:57-9.
- Yoshino T, Tanaka T, Sato Y. Differential diagnosis of chronic lymphocytic leukemia/small lymphocytic lymphoma and other indolent lymphomas, including mantle cell lymphoma. *J Clin Exp Hematop*. 2020;60(4):124-9.
- Choi SM, O'Malley DP. Diagnostically relevant updates to the 2017 WHO classification of lymphoid neoplasms. *Ann Diagn Pathol*. 2018;37:67-74.
- Matutes E. The 2017 WHO update on mature T- and natural killer (NK) cell neoplasms. *Int J Lab Hematol*. 2018;40 Suppl 1:97-103.
- H Stein SP, LM Weiss et al. . WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th edition ed. Swerdlow SH CE, Harris NL, et al., editors editor. Lyon: International Agency for Research on Cancer 2017.
- Ansell SM. Hodgkin lymphoma: A 2020 update on diagnosis, risk-stratification, and management. *Am J Hematol*. 2020;95(8):978-89.
- Goyal A, LeBlanc RE, Carter JB. Cutaneous B-Cell Lymphoma. *Hematol Oncol Clin North Am*. 2019;33(1):149-61.
- Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. *Blood*. 2019;133(16):1703-14.
- Foppoli M, Ferreri AJ. Gamma-delta t-cell lymphomas. *Eur J Haematol*. 2015;94(3):206-18.
- Malachowski SJ, Sun J, Chen PL, Seminario-Vidal L. Diagnosis and Management of Cutaneous B-Cell Lymphomas. *Dermatol Clin*. 2019;37(4):443-54.
- Larocca C, Kupper T. Mycosis Fungoides and Sézary Syndrome: An Update. *Hematol Oncol Clin North Am*. 2019;33(1):103-20.
- Ahn JS, Okal R, Vos JA, Smolkin M, Kanate AS, Rosado FG. Plasmablastic lymphoma versus plasmablastic myeloma: an ongoing diagnostic dilemma. *J Clin Pathol*. 2017;70(9):775-80.
- Ma Z, Shi Y, Pang X, Li X, Cui W, Zhang W. Clinicopathologic features and prognostic analysis of Waldenstrom ring B-cell lymphoma. *Medicine (Baltimore)*. 2020;99(2):e18670.
- Olszewska-Szopa M, Wróbel T. Gastrointestinal non-Hodgkin lymphomas. *Adv Clin Exp Med*. 2019;28(8):1119-24.
- Juárez-Salcedo LM, Sokol L, Chavez JC, Dalia S. Primary Gastric Lymphoma, Epidemiology, Clinical Diagnosis, and Treatment. *Cancer Control*. 2018;25(1):1073274818778256.
- Peng JC, Zhong L, Ran ZH. Primary lymphomas in the gastrointestinal tract. *J Dig Dis*. 2015;16(4):169-76.
- Warsame R, Gertz MA, Lacy MQ, Kyle RA, Buadi F, Dingli D, et al. Trends and outcomes of modern staging of solitary plasmacytoma of bone. *Am J Hematol*. 2012;87(7):647-51.
- Basavaiah SH, Lobo FD, Philipose CS, Suresh PK, Sreeram S, Kini H, et al. Clinicopathological spectrum of solitary Plasmacytoma: a single center experience from coastal India. *BMC Cancer*. 2019;19(1):801.
- Chisholm KM, Ohgami RS, Tan B, Hasserjian RP, Weinberg OK. Primary lymphoma of bone in the pediatric and young adult population. *Hum Pathol*. 2017;60:1-10.
- Messina C, Christie D, Zucca E, Gospodarowicz M, Ferreri AJ. Primary and secondary bone lymphomas. *Cancer Treat Rev*. 2015;41(3):235-46.
- Power DG, McVey GP, Korpanty G, Treacy A, Dervan P, O'Keane C, et al. Primary bone lymphoma: single institution case series. *Ir J Med Sci*. 2008;177(3):247-51.

36. Piris MA, Onaindí A, Mollejo M. Splenic marginal zone lymphoma. *Best Pract Res Clin Haematol.* 2017;30(1-2):56-64.
37. Yamada Y, Miura M, Tagari M, Oshimi K, Shiragata T, Suga W, et al. [Splenic diffuse red pulp small B-cell lymphoma diagnosed by splenectomy initially mimicking hairy cell leukemia-Japanese variant]. *Rinsho Ketsueki.* 2018;59(3):281-6.
38. Suzuki T, Miyoshi H, Shimono J, Kawamoto K, Arawaka F, Furuta T, et al. Clinicopathological analysis of splenic red pulp low-grade B-cell lymphoma. *Pathol Int.* 2020;70(5):280-6.
39. Shimono J, Miyoshi H, Kiyasu J, Sato K, Kamimura T, Eto T, et al. Clinicopathological analysis of primary splenic diffuse large B-cell lymphoma. *Br J Haematol.* 2017;178(5):719-27.
40. Löw S, Batchelor TT. Primary Central Nervous System Lymphoma. *Semin Neurol.* 2018;38(1):86-94.
41. Bödör C, Alpár D, Marosvári D, Galik B, Rajnai H, Bátai B, et al. Molecular Subtypes and Genomic Profile of Primary Central Nervous System Lymphoma. *J Neuro-pathol Exp Neurol.* 2020;79(2):176-83.
42. Al-Hamadani M, Habermann TM, Cerhan JR, Macon WR, Maurer MJ, Go RS. Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011. *Am J Hematol.* 2015;90(9):790-5.
43. Fan Y, Dong L, BS OU, Xu HM, Zheng SF, Wang AR, et al. [Clinicopathological features of de novo CD5-positive diffuse large B-cell lymphoma]. *Zhonghua Bing Li Xue Za Zhi.* 2020;49(5):448-53.
44. Ayyappan S, William BM. Marginal Zone Lymphoma: Clinicopathologic Variations and Approaches to Therapy. *Curr Oncol Rep.* 2018;20(4):33.
45. Ivancević TD, Kurtović NK, Knezević V, Bogdanović A, Mihaljević B, Božić B, et al. The role of immunophenotyping in differential diagnosis of chronic lymphocytic leukemia. *Srp Arh Celok Lek.* 2014;142(3-4):197-203.
46. Geisler CH, Larsen JK, Hansen NE, Hansen MM, Christensen BE, Lund B, et al. Prognostic importance of flow cytometric immunophenotyping of 540 consecutive patients with B-cell chronic lymphocytic leukemia. *Blood.* 1991;78(7):1795-802.
47. Yang WI, Zukerberg LR, Motokura T, Arnold A, Harris NL. Cyclin D1 (Bcl-1, PRAD1) protein expression in low-grade B-cell lymphomas and reactive hyperplasia. *Am J Pathol.* 1994;145(1):86-96.
48. Vogt N, Dai B, Erdmann T, Berdel WE, Lenz G. The molecular pathogenesis of mantle cell lymphoma. *Leuk Lymphoma.* 2017;58(7):1530-7.
49. Mohanty A, Sandoval N, Phan A, Nguyen TV, Chen RW, Budde E, et al. Regulation of SOX11 expression through CCND1 and STAT3 in mantle cell lymphoma. *Blood.* 2019;133(4):306-18.
50. Jaso JM, Yin CC, Wang SA, Miranda RN, Jabcuga CE, Chen L, et al. Clinicopathologic features of CD5-positive nodal marginal zone lymphoma. *Am J Clin Pathol.* 2013;140(5):693-700.
51. Yamaguchi M, Nakamura N, Suzuki R, Kagami Y, Okamoto M, Ichinohasama R, et al. De novo CD5+ diffuse large B-cell lymphoma: results of a detailed clinicopathological review in 120 patients. *Haematologica.* 2008;93(8):1195-202.
52. Lai R, Arber DA, Chang KL, Wilson CS, Weiss LM. Frequency of bcl-2 expression in non-Hodgkin's lymphoma: a study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia. *Mod Pathol.* 1998;11(9):864-9.
53. Ok CY, Medeiros LJ. High-grade B-cell lymphoma: a term re-purposed in the revised WHO classification. *Pathology.* 2020;52(1):68-77.
54. Naresh KN, Ibrahim HA, Lazzi S, Rince P, Onorati M, Ambrosio MR, et al. Diagnosis of Burkitt lymphoma using an algorithmic approach--applicable in both resource-poor and resource-rich countries. *Br J Haematol.* 2011;154(6):770-6.
55. Schwab U, Stein H, Gerdes J, Lemke H, Kirchner H, Schaadt M, et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. *Nature.* 1982;299(5878):65-7.
56. Lai R, Weiss LM, Chang KL, Arber DA. Frequency of CD43 expression in non-Hodgkin lymphoma. A survey of 742 cases and further characterization of rare CD43+ follicular lymphomas. *Am J Clin Pathol.* 1999;111(4):488-94.
57. Zhang F, Luo D, Luo X, Chen Y, Xu J, Chen J, et al. [Expression and significance of HGAL and LMO2 in follicular lymphoma]. *Zhonghua Bing Li Xue Za Zhi.* 2016;45(2):83-5.
58. Krishnan J, Wallberg K, Frizzera G. T-cell-rich large B-cell lymphoma. A study of 30 cases, supporting its histologic heterogeneity and lack of clinical distinctiveness. *Am J Surg Pathol.* 1994;18(5):455-65.
59. Cheng CL, O'Connor S. T cell-rich lymphoid infiltrates with large B cells: a review of key entities and diagnostic approach. *J Clin Pathol.* 2017;70(3):187-201.
60. Hartmann S, Döring C, Jakobus C, Rengstl B, Newrzela S, Tousseyn T, et al. Nodular lymphocyte predominant hodgkin lymphoma and T cell/histiocyte rich large B cell lymphoma--endpoints of a spectrum of one disease? *PLoS One.* 2013;8(11):e78812.
61. van der Weyden CA, Pileri SA, Feldman AL, Whistock J, Prince HM. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions. *Blood Cancer J.* 2017;7(9):e603.
62. Josimovic-Alasevic O, Dürkop H, Schwarting R, Backé E, Stein H, Diamantstein T. Ki-1 (CD30) antigen is released by Ki-1-positive tumor cells in vitro and in vivo. I. Partial characterization of soluble Ki-1 antigen and detection of the antigen in cell culture supernatants and in serum by an enzyme-linked immunosorbent assay. *Eur J Immunol.* 1989;19(1):157-62.
63. Vega F, Medeiros LJ. A suggested immunohistochemical algorithm for the classification of T-cell lymphomas involving lymph nodes. *Hum Pathol.* 2020;102:104-16.

64. Xu ML, Gabali A, Hsi ED, Fedoriw Y, Vij K, Salama ME, et al. Practical Approaches on CD30 Detection and Reporting in Lymphoma Diagnosis. *Am J Surg Pathol*. 2020;44(2):e1-e14.
65. Medeiros LJ, Elenitoba-Johnson KS. Anaplastic Large Cell Lymphoma. *Am J Clin Pathol*. 2007;127(5):707-22.
66. Campuzano-Zuluaga G, Cioffi-Lavina M, Lossos IS, Chapman-Fredricks JR. Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases. *Leuk Lymphoma*. 2013;54(11):2405-11.
67. Vose J, Armitage J, Weisenburger D. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. *J Clin Oncol*. 2008;26(25):4124-30.
68. Rangoonwala HI, Cascella M. Peripheral T-Cell Lymphoma. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2021, StatPearls Publishing LLC.; 2021.
69. Hue SS, Oon ML, Wang S, Tan SY, Ng SB. Epstein-Barr virus-associated T- and NK-cell lymphoproliferative diseases: an update and diagnostic approach. *Pathology*. 2020;52(1):111-27.
70. Gu YY, Luo B, Li CY, Huang LS, Chen G, Feng ZB, et al. Expression and clinical significance of neuropilin-1 in Epstein-Barr virus-associated lymphomas. *Cancer Biomark*. 2019;25(3):259-73.
71. Aye R, Ofori MEO, Wright E, Quaye O. Epstein Barr Virus Associated Lymphomas and Epithelia Cancers in Humans. *J Cancer*. 2020;11(7):1737-50.
72. Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. *Blood*. 2015;125(15):2323-30.
73. Chen BJ, Chuang SS. Lymphoid Neoplasms With Plasmablastic Differentiation: A Comprehensive Review and Diagnostic Approaches. *Adv Anat Pathol*. 2020;27(2):61-74.
74. Pham A, Mahindra A. Solitary Plasmacytoma: a Review of Diagnosis and Management. *Curr Hematol Malig Rep*. 2019;14(2):63-9.
75. Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson SY, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. *J Hematol Oncol*. 2018;11(1):10.
76. Firsova MV, Mendeleeva LP, Kovrigina AM, Solovev MV, Savchenko VG. Plasmacytoma in patients with multiple myeloma: morphology and immunohistochemistry. *BMC Cancer*. 2020;20(1):346.
77. Tokatli F, Puyan FO, Alas RC, Tuncbilek N, Uzal C. Extramedullary plasmacytoma: clinicopathology, immunohistochemistry and therapeutic approach to a case with a tonsillar site. *Hematol Oncol Stem Cell Ther*. 2008;1(4):241-5.
78. Wang W, Lin P. Lymphoplasmacytic lymphoma and Waldenström macroglobulinaemia: clinicopathological features and differential diagnosis. *Pathology*. 2020;52(1):6-14.
79. Vitolo U, Ferreri AJ, Montoto S. Lymphoplasmacytic lymphoma-Waldenström's macroglobulinemia. *Crit Rev Oncol Hematol*. 2008;67(2):172-85.
80. Morice WG, Chen D, Kurtin PJ, Hanson CA, McPhail ED. Novel immunophenotypic features of marrow lymphoplasmacytic lymphoma and correlation with Waldenström's macroglobulinemia. *Mod Pathol*. 2009;22(6):807-16.
81. Martinez-Cabrales SA, Walsh S, Sade S, Shear NH. Lymphomatoid papulosis: an update and review. *J Eur Acad Dermatol Venereol*. 2020;34(1):59-73.
82. Tse E, Kwong YL. Diagnosis and management of extranodal NK/T cell lymphoma nasal type. *Expert Rev Hematol*. 2016;9(9):861-71.
83. Jeong SH. Extranodal NK/T cell lymphoma. *Blood Res*. 2020;55(S1):S63-s71.
84. Asano N, Kato S, Nakamura S. Epstein-Barr virus-associated natural killer/T-cell lymphomas. *Best Pract Res Clin Haematol*. 2013;26(1):15-21.
85. Ko YH, Karnan S, Kim KM, Park CK, Kang ES, Kim YH, et al. Enteropathy-associated T-cell lymphoma--a clinicopathologic and array comparative genomic hybridization study. *Hum Pathol*. 2010;41(9):1231-7.
86. Tian S, Xiao SY, Chen Q, Liu H, Ping J. Monomorphic epitheliotropic intestinal T-cell lymphoma may mimic intestinal inflammatory disorders. *Int J Immunopathol Pharmacol*. 2019;33:2058738419829387.